Misplaced Pages

Tuvirumab is a human monoclonal antibody for the treatment of patients with chronic hepatitis B. It has undergone Phase I clinical trials in 2001.

References

1. Heijtink RA, van Nunen AB, van Bergen P, Ostberg L, Osterhaus AD, de Man RA (August 2001). "Administration of a human monoclonal antibody (TUVIRUMAB) to chronic hepatitis B patients pre-treated with lamivudine: monitoring of serum TUVIRUMAB in immune complexes". Journal of Medical Virology. 64 (4): 427–34. doi:10.1002/jmv.1068. PMID 11468726. S2CID 28825387.
2. van Nunen AB, Baumann M, Manns MP, Reichen J, Spengler U, Marschner JP, de Man RA (June 2001). "Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients". Liver. 21 (3): 207–12. doi:10.1034/j.1600-0676.2001.021003207.x. hdl:1765/66667. PMID 11422784.

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Monoclonal antibodies
• Experimental antiviral drugs
• Antiinfective agent stubs
• Monoclonal antibody stubs